7,622.05

+41.98

+0.55%

52,295.52

+525.21

+1.01%

25,602.70

+165.71

+0.65%

2,841.58

+29.74

+1.06%

4.8880

-0.0410

-0.83%

18.87

-0.55

-2.83%

3,978.70

+79.80

+2.05%

77,391.98

-462.02

-0.59%

Crude Oil Dec 26

96.50

-7.62

-7.32%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGM - Nasdaq Real Time Price USD

Larimar Therapeutics, Inc. (LRMR)

2.3850 -0.0850 (-3.44%)

As of 12:04:35 PM EST. Market Open.

Trade LRMR on Coinbase

Loading Chart for LRMR

Chart Range Bar

Interval:

In partnership with ChartIQ

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

Here’s What Citi Thinks About Larimar Therapeutics (LRMR)

Here’s What Citi Thinks About Larimar Therapeutics (LRMR)

LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)

Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)

Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp

Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Mobilize your Website

View Site in Mobile | Classic

Share by: